
MannKind (MNKD) Stock Forecast & Price Target
MannKind (MNKD) Analyst Ratings
Bulls say
MannKind Corporation's continued advancement of its orphan lung pipeline positions the company for long-term diversification and growth, underscoring its strategic focus on expanding revenue streams. The management's commitment to enhancing education and marketing efforts, particularly through targeted campaigns for healthcare professionals, may further drive uptake of its inhaled therapeutic products. Additionally, with positive patient feedback on Tyvaso DPI and its market share growth, alongside the promising potential of Furoscix, MannKind is well-positioned to capitalize on emerging opportunities in the pharmaceutical landscape.
Bears say
MannKind Corp's stock outlook remains negative due to concerns over increased competition, particularly following the approval of a competitor's product, which influenced a significant share price decline. The potential for challenges to the company's intellectual property and the possibility of negative trial results raises doubts about the timely commercialization of their therapies, further weakening market confidence. Additionally, the presence of well-capitalized rivals with established products threatens to diminish MannKind's market share and pricing power in key therapeutic areas.
This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.
MannKind (MNKD) Analyst Forecast & Price Prediction
Start investing in MannKind (MNKD)
Order type
Buy in
Order amount
Est. shares
0 shares